Vancomycin-resistant Staphylococcus aureus: No apocalypse now

Clinical Microbiology and Infection

Volumn 9, Issue 8, 2003, Pages 761-765

  Goldstein, F W ^a   Kitzis, M D ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

GISA; Staphylococcus aureus; Vancomycin resistance; VRSA

Indexed keywords

AMINOCYCLITOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; ORITAVANCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; EDITORIAL; MEDICAL LITERATURE; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0141850971     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00734.x     Document Type: Editorial

References (30)

1. Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 1997; 350: 1644-45.
2. Hiramatsu KN, Aritaka H, Hanaki S et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
3. Johnson AP. Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience? J Antimicrob Chemother 1998; 42: 289-91.
4. Cercenado E. Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem? Clin Microbiol Infect 2000; 6: 517-18.
5. Chesneau O, Morvan A, El Sohl N. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 2000; 45: 887-90.
6. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43(7): 1747-53.
7. Guerin F, Buu-Hoï A, Mainardi JL et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 2000; 38(8): 2985-8.
8. Vaudaux P, François P, Berger-Bächi B, Lew DP. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 2001; 47(2): 163-70.
9. Howe RA, Wootton M, Bennett PM, MacGowan AP, Walsh TR. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J Clin Microbiol 1999; 3068-71.
10. Rotun SS, McMath V, Schoonmaker DJ et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5: 147-9.
11. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-01.
12. Sugino Y, Iinuma Y, Ichiyama S et al. In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2000; 38: 159-67.
13. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001; 39(2): 591-5.
14. Ward PB, Johnson PDR, Brabsch EA, Mayall BC, Grayson ML. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. MJA 2001; 175: 480-3.
15. Samson SY, Wong PL, Ho PC, Woo Y, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29: 760-7.
16. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 2001; 61(1): 1-7.
17. Ploy MC, Grélaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
18. Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995; 171: 1646-50.
19. Quincampoix JC, Carbonne A, Loyer D et al. Follow-up of a nosocomial outbreak of methicillin-resistant strains of Staphylococcus aureus (MRSA) with decreased susceptibility to teicoplanin (DST) [abstract C167]. In: 37th ICAAC, Toronto. 1997.
20. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new-model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
21. Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother 1991; 27: 71-9.
22. Brunet F, Vedel G, Dreyfus F et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1990; 9: 145-7.
23. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992; 166: 1066-72.
24. Kaatz G, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162: 103-8.
25. Manquat G, Croize J, Stahl JP, Meyran M, Hirtz P, Micoud M. Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia. J Antimicrob Chemother 1992; 29: 731-2.
26. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44(9): 2276-85.
27. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother 1993; 37: 2432-7.
28. Ariza J, Pujol M, Cabo J et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353(9164): 1587-8.
29. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15.
30. Vancomycin-resistant Staphylococcus aureus. Pennsylvania 2002. MMWR 2002; 51: 902.